ImmunityBio (IBRX) Stock Overview
A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
IBRX Community Fair Values
Create NarrativeSee what 93 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ImmunityBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.91 |
| 52 Week High | US$12.43 |
| 52 Week Low | US$1.95 |
| Beta | 0.13 |
| 1 Month Change | -0.13% |
| 3 Month Change | 7.47% |
| 1 Year Change | 186.59% |
| 3 Year Change | 372.24% |
| 5 Year Change | -21.84% |
| Change since IPO | -79.56% |
Recent News & Updates
Recent updates
ImmunityBio: None Of The Moonshots Is Priced In
Summary ImmunityBio is rated a strong buy, driven by ANKTIVA's FDA approval for BCG-unresponsive NMIBC and significant pipeline expansion potential. Current valuation reflects success in bladder cancer and BCG-naïve expansion, but assigns limited value to systemic immunotherapy potential in NSCLC or other types of cancer. Key near-term catalysts include phase 3 NSCLC data and BCG-naïve bladder cancer trial results, both of which could unlock substantial upside. Liquidity risk exists due to high cash burn and convertible debt, but European and UAE approvals, plus pipeline moonshots, provide asymmetric upside. Read the full article on Seeking Alpha
IBRX: FDA Review Timeline For Bladder Cancer Will Drive Future Upside
Analysts have reset their price target on ImmunityBio from $23 to $15. This reflects updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions.
IBRX: Saudi Rollout And FDA Label Review Will Drive Future Upside
Analysts have raised their ImmunityBio price target from $11.00 to $12.00, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers of the revision. What’s in the News for ImmunityBio ImmunityBio shares recently reached a 3 month high, with investors focused on July catalysts including the commercial rollout of Anktiva in Saudi Arabia and upcoming updates on second quarter sales performance.
IBRX: Potential Index Inclusion Will Support Cancer Franchise Expansion
Analysts have lowered their ImmunityBio price target slightly from $13.50 to $13.00 as they refresh assumptions around discount rates, revenue growth, margins, and future P/E expectations. What’s in the News for ImmunityBio Retail traders are speculating that ImmunityBio stock could shift from the Russell 2000 to the Russell 1000 based on a cutoff around US$5.7b, with some traders expecting potential index fund buying and changes in volatility if inclusion occurs, according to recent Stocktwits sentiment data and after hours trading moves.Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking AlphaImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking AlphaShareholder Returns
| IBRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.9% | -2.1% | -1.1% |
| 1Y | 186.6% | 36.5% | 11.7% |
Return vs Industry: IBRX exceeded the US Biotechs industry which returned 36.5% over the past year.
Return vs Market: IBRX exceeded the US Market which returned 11.7% over the past year.
Price Volatility
| IBRX volatility | |
|---|---|
| IBRX Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: IBRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IBRX's weekly volatility has decreased from 15% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 688 | Rich Adcock | immunitybio.com |
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
ImmunityBio, Inc. Fundamentals Summary
| IBRX fundamental statistics | |
|---|---|
| Market cap | US$8.63b |
| Earnings (TTM) | -US$992.36m |
| Revenue (TTM) | US$165.79m |
Is IBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBRX income statement (TTM) | |
|---|---|
| Revenue | US$165.79m |
| Cost of Revenue | US$1.10m |
| Gross Profit | US$164.70m |
| Other Expenses | US$1.16b |
| Earnings | -US$992.36m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 99.34% |
| Net Profit Margin | -598.56% |
| Debt/Equity Ratio | -113.7% |
How did IBRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/16 23:21 |
| End of Day Share Price | 2026/09/16 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmunityBio, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Andres Maldonado | H.C. Wainwright & Co. |